Skip to main content
OpenTrials
Completed

NCT Number: NCT02663999

A Pharmacokinetic Study to Assess Dose Proportionality, Safety and Tolerability of Diazepam Nasal Spray in Healthy Adult Volunteers

This is a single-center, two-period, randomized, open-label, crossover pharmacokinetic (PK) study in healthy adult volunteers to evaluate dose proportionality of diazepam nasal spray using two dose levels

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Age range

18 year–65 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 1

Primary location

Site #001

Dallas, Texas, 75247, United States

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Screening body weight 88 to 111 kg, inclusive;
  • General good health with no clinically significant abnormalities that would affect ability to complete study as determined by medical history, physical examination, visual evaluation of the septum and turbinates to document baseline anatomy, electrocardiogram, clinical laboratory test results;
  • Negative drug and alcohol testing;
  • Negative pregnancy test for female subjects of childbearing potential.

Exclusion criteria

  • Subject who is not surgically sterile or female subject who is less than 2 years postmenopausal, and who does not agree to use a highly effective birth control method during the study and up to 3 months after the last dose of investigational product;
  • In the judgment of the Investigator, any clinically significant abnormality (such as septal perforations) or illness that would interfere with participation in this study as determined by medical history, physical examination (including visual exam of septum and turbinates), ECG, clinical laboratory results, or other screening safety tests;
  • Any other condition and/or situation that causes the investigator to deem a subject unsuitable for the study.

Treatment and study plan

diazepam nasal spray

Drug

diazepam nasal spray at two dose levels (DL). One dose of diazepam nasal spray is administered as two intranasal sprays; one in each nostril using a nasal spray device.

Other names: PLUMIAZ™ (diazepam) Nasal Spray

Primary outcomes

  1. Maximum measured plasma concentration (Cmax)

    Time frame: within 15 minutes prior to dosing and at specified time points up to 24 hours post-dose

  2. Area under the concentration curve from time 0 to the concentration at 24 hours (AUC0-24)

    Time frame: within 15 minutes prior to dosing and at specified time points up to 24 hours post-dose

  3. Area under the concentration curve from time 0 to infinity (AUCinf)

    Time frame: within 15 minutes prior to dosing and at specified time points up to 24 hours post-dose

  4. Apparent total body clearance of drug from plasma (CL/F)

    Time frame: within 15 minutes prior to dosing and at specified time points up to 24 hours post-dose

Secondary outcomes

  1. Number of patients with adverse events (AEs) including serious AEs

    Time frame: up to 21 days

  2. Change in focused nasal exam

    Time frame: within 30 minutes prior to dosing and at specified time points up to 24 hours post-dose

  3. Taste change questionnaire

    Time frame: from 5 minutes up to 24 hours post-dose

    If patient reports a change in taste associated with diazepam nasal spray, questionnaire to be completed by research staff.

Sponsors and collaborators

Lead sponsor

Acorda Therapeutics

Industry

Registry information

Official study title

A Two-Period, Randomized, Open-Label, Crossover Pharmacokinetic Study to Assess Dose Proportionality, Safety and Tolerability of Diazepam Nasal Spray in Healthy Adult Volunteers

Important dates

Study start
2016
Primary completion
2016
Study completion
2016
First posted
Jan 26, 2016
Registry last updated
Jun 13, 2016

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.